Jain PharmaBiotech, June 2012, Pages: 485
nucleotide RNAs termed siRNAs that are used in a sequence-specific manner to recognize and destroy complementary RNA. The report compares RNAi with other antisense approaches using oligonucleotides, aptamers
Takeda Pacific, July 2007, Pages: 131
RNA Interference for Drug R&D: Applications, Alliances, Companies and WW Market to 2011 This report assesses the RNA interference market for drug R&D. RNA interference (RNAi) has been hailed in the
Global Industry Analysts, Inc., April 2011, Pages: 802
institutions has witnessed a substantial growth.
The US and Europe together account for a lion’s share of the global RNAimarket, as stated by the new Global Industry Analysts' market research report on RNA
Business Insights, June 2007, Pages: 244
litigation?
MicroRNA
Tuschl III patents
Zamore and other patents
Regulatory considerations for RNAi therapies
Conclusions
Chapter 8 RNAi markets and trends
Summary
Introduction
The RNAimarket
Business Insights, Sep 2008, Pages: 253
satisfaction and five new Phase II/III RNAi agents profiled in this report."
RNA interference continues to offer significant promise for a host of therapeutic treatments. Potentially any disease-causing gene
TriMark Publications, Dec 2008, Pages: 147
study. This is known as gene knockdown. This field has rapidly emerged as a fast-growing new market.
The purpose of this report is to review the market for RNAi testing equipment and supplies. RNAi is a
GBI Research, Feb 2010, Pages: 89
into the unmet needs in the pharmaceutical and healthcare market and potential segments where RNA therapies can prove to be useful. This pharma report also delves deep into the market potential that RNA
Business Insights, May 2005 report which analyzes the latest trends in the RNAimarket, allowing pharmaceutical companies to decide which areas of RNAi technologies to invest in, to improve drug attrition rates and develop new
Markets and Markets, Nov 2010, Pages: 311
. This report will also provide market tables for covering the sub-segments and micro-markets. In addition, the report also provides more than 20 company profiles covering all the sub-segments.
What
Fuji-Keizai USA, Inc, Feb 2006, Pages: 130
Stranded RNA (dsRNA)
1.1.3 Short interfering RNA; Small interfering RNA (siRNA)
1.1.4 Short Hairpin RNA (shRNA)
1.1.5 DNA-directed RNAi (ddRNAi)
1.1.6 MicroRNA (miRNA)
1.2 Current US RNAiMarket
Decision Resources, Inc., Feb 2010, Pages: 32
technologies, including RNA interference (RNAi), to the development of novel antivirals.
Which companies are developing RNA and RNAi-based antivirals? Which RNA-based technologies are the most advanced in
Jain PharmaBiotech, June 2012, Pages: 225
reaction
RNA interference and cytogenetics
RNA-induced transcriptional silencing complex
Single cell genetics by siRNA ablation
RNAi and cancer cytogenetics
Role of miRNAs in cancer cytogenetics
Jain PharmaBiotech, June 2012, Pages: 639
diagnosis and therapeutics of cancer
Antisense compounds in clinical trials
RNA interference
Basics of RNAi
Comparison of antisense and RNAiRNAi applications in oncology
siRNA-based cancer immunotherapy
Jain PharmaBiotech, June 2012, Pages: 658
such as RNA interference (RNAi), further increasing the therapeutic applications. This report takes broad overview of gene therapy and is the most up-to-date presentation from the author on this topic
Decision Resources, Inc., Aug 2005, Pages: 19
(ASOs), RNA interference (RNAi), and microRNA (miRNA). Companies have been testing ASOs in the clinic for ten years, and one antisense product, fomivirsen (Isis Pharmaceuticals’ Vitravene), is on the
Business Insights, April 2005, Pages: 186
.
Key questions answered in this report
- What will the market for lab-on-a-chip (LOC), nanoenabled drug discovery and RNAi technology be worth in 2012?
- How can these three technologies be effectively
Fuji-Keizai USA, Inc, Jan 2011, Pages: 134
MicroRNA Screening Equipment
4.3 Cell Culture Equipment for Tissue Engineering
Common Research Item (4.3.1 – 4.3.7)
- Market Overview
- Leading Players (Company Name, Contact Information, Public or Private
Fuji-Keizai USA, Inc, Feb 2011, Pages: 122
MicroRNA Screening Equipment
4.3 Cell Culture Equipment for Tissue Engineering
Common Research Item (4.3.1 – 4.3.7)
- Market Overview
- Leading Players (Company Name, Contact Information, Public or Private
Beachhead Consulting, Sep 2006
microarray applications on the healthcare and pharmaceutical industries is examined in this report and reveals the market for the latest products and technologies as potentially one of the fastest growing
